



**Howard M. Sandler, M.D.**  
**Professor of Radiation Oncology**  
**Senior Associate Chair of Radiation Oncology**

Dr. Howard Sandler graduated from the University of Connecticut Medical School in 1985 and received his radiation oncology training at the Hospital of the University of Pennsylvania, Philadelphia. He has been on the staff at The University of Michigan since 1989 and currently serves as the associate chair of radiation oncology. Dr. Sandler has particular expertise in prostate cancer and is the principal investigator of a national protocol studying chemotherapy and radiotherapy for prostate cancer. He is the author of more than 100 peer-reviewed publications.

For more information about Dr. Sandler, please visit [www.med.umich.edu/radonc/dep/facsand.htm](http://www.med.umich.edu/radonc/dep/facsand.htm).

**Clinical Specialty:** Radiation Oncology

**Clinical Interests:** Prostate and genitourinary tumors

**Research Interests:** Dose escalation for carcinoma of the prostate.

**Name**

Howard M. Sandler, MD

**Title(s)**

Professor, Senior Associate Chair

**Primary Location**

University of Michigan

**Mailing Address**

Department of Radiation Oncology  
University of Michigan Health System  
1500 East Medical Center Drive, Box 0010  
Ann Arbor, Michigan 48109-0010

**Phone**

734-936-9338

**Fax**

734-763-7371

**Specialties**

Prostate cancer and other genitourinary malignancies. Brain tumors. Skin cancer.

**Board Certifications**

American Board of Radiology

**Clinical and Research Interests**

Research interests include dose escalation for prostate cancer and brain tumors. Also, as chair of the RTOG GU committee, Dr. Sandler is involved in the design of large national clinical trials.

**Medical School(s) Attended**

University of Connecticut

**Class of**

1985

### **Residencies**

University of Pennsylvania

### **Recent Publications**

Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMan MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. *J Urol* 172:S3-5, 2004.

Kuefer R, Volkmer BG, Loeffler M, Shen RL, Kempf L, Gschwend JE, Hautmann RE, Sandler HM\*, Rubin MA\*: Comparison of outcome of external radiation therapy versus radical prostatectomy in lymph node positive prostate cancer patients. *Prostate Cancer & Prostatic Diseases* 7:343-9, 2004. \*Sandler and Rubin contributed equally

McLaughlin PW, Narayana V, Meriwitz A, Troyer S, Roberson PL, Gonda R Jr, Sandler H, Marsh L, Lawrence T, Kessler M: Vessel-sparing prostate radiotherapy: Dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRI. *Int J Radiat Oncol Biol Phys* 61:20-31, 2005.

Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all? *Int J Radiat Oncol Biol Phys* 61:409-414, 2005.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A: Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. *Int J Radiat Oncol Biol Phys* 61:415-419, 2005.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL: Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone: A multi-institutional pooled analysis. *J Urol* 173:797-802, 2005.

Taylor JMG, Yu M, Sandler HM: Individualized predictions of disease progression following radiation therapy for prostate cancer. *J Clin Oncol* 23:816-825, 2005.

Khor LY, DeSilvio M, Al-Saleem T, Hammond ME, Grignon DJ, Sause W, Pilepich M, Okunieff P, Sandler H, Pollack A: MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group protocol 8610. *Cancer* 104:962-967, 2005.

Feigenberg SJ, Lee WR, DeSilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H: Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. *Int J Radiat Oncol Biol Phys* 62:956-964, 2005.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA ERA. *Int J Radiat Oncol Biol Phys* 63:795-799, 2005.

Chakravarti A, Winter K, Wu C-L, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W: Expression of the epidermal growth factor receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 62:309-317, 2005.

Miller DC, Sanda MG, Dunn RL, Montie JE, Pimental H, Sandler HM, McLaughlin PW, Wei JT: Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *J Clin Oncol* 23:2772-2780, 2005.

Litzenberg DW, Balter JM, Lam KL, Sandler HM, Ten Haken RK: Retrospective analysis of prostate patients with implanted gold markers using off-line and adaptive therapy protocols. *Int J Radiat Oncol Biol Phys* 63: 123-133, 2005.

Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC: Ototoxicity of cisplatin plus standard radiation therapy versus accelerated radiation therapy in glioblastoma patients. *J Neuro-Oncol* 2005.

Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H: A Phase II study of external beam radiation therapy combined with permanent source brachytherapy for intermediate risk clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. *Int J Radiat Oncol Biol Phys* 64:804-809, 2006